scholarly journals Immunohistochemical expression of vimentin, calponin and HHF-35 in salivary gland tumors

2007 ◽  
Vol 18 (3) ◽  
pp. 192-197 ◽  
Author(s):  
Roberta Barroso Cavalcante ◽  
Fernanda Ferreira Lopes ◽  
Andréa Soares Ferreira ◽  
Roseana de Almeida Freitas ◽  
Lélia Batista de Souza
Keyword(s):  
Salivary Gland ◽  
Myoepithelial Cells ◽  
Salivary Gland Tumors ◽  
Low Grade ◽  
Tubular Structures ◽  
Immunohistochemical Markers ◽  
Adenoid Cystic ◽  
Peripheral Cells ◽  
Diffuse Distribution ◽  
Labeling Pattern

Myoepithelial cells present a complex immunophenotype, with the expression of proteins varying according to the stage of normal or neoplastic differentiation of the cell. In order to evaluate the immunohistochemical markers expressed by these cells, a panel of antibodies composed of vimentin, calponin and HHF-35 was applied to 28 salivary gland tumors. The results demonstrated a higher percent sensitivity of vimentin and calponin compared to HHF-35. However, calponin and HHF-35 presented a focal labeling pattern in contrast with the diffuse distribution of vimentin. The cells predominantly stained by all tested antibodies included nonluminal cells in duct-like and tubular structures, such as those seen in pleomorphic adenomas and adenoid cystic carcinomas, as well as cells in the cords and nests of polymorphous low-grade adenocarcinomas and peripheral cells of sheets and nests of myoepitheliomas. In conclusion, the combination of calponin and vimentin is suggested for the identification of myoepithelial cells in salivary gland tumors.

The Myoepithelial Immunophenotype in 135 Benign and Malignant Salivary Gland Tumors Other Than Pleomorphic Adenoma

1999 ◽  
Vol 123 (9) ◽  
pp. 801-806 ◽  
Author(s):  
Anil R. Prasad ◽  
Adnan T. Savera ◽  
Allen M. Gown ◽  
Richard J. Zarbo
Keyword(s):  
Smooth Muscle ◽  
Salivary Gland ◽  
Salivary Gland Tumors ◽  
Low Grade ◽  
Salivary Duct ◽  
Not Otherwise Specified ◽  
Adenoid Cystic ◽  
Myoepithelial Differentiation ◽  
Specific Proteins ◽  
Malignant Salivary Gland Tumors

Abstract Background.—We have previously studied the immunoreactivity of 3 novel smooth muscle–specific proteins, α-smooth muscle actin, smooth muscle myosin heavy chains, and calponin, to assess myoepithelial differentiation in pleomorphic adenomas. Objective.—To further expand our knowledge of myoepithelial differentiation in other benign and malignant salivary gland tumors. Design.—Formalin-fixed paraffin sections of 135 salivary gland tumors with associated normal glands were stained with monoclonal antibodies using the avidin-biotin complex immunoperoxidase method and enzymatic and microwave heat–induced epitope retrieval. Results.—In adenoid cystic carcinomas and epithelial-myoepithelial carcinomas, all 3 markers exclusively highlighted the myoepithelial cell components and the epithelial cells were entirely negative. No immunostaining was detected in canalicular adenomas, oncocytomas, Warthin tumors, acinic cell carcinomas, mucoepidermoid carcinomas, squamous cell carcinomas, and polymorphous low-grade adenocarcinomas. Salivary duct carcinomas and adenocarcinomas, not otherwise specified had a distinctive pattern of uniform periductal staining of reactive myofibroblastic cells, and in salivary duct carcinomas some ducts retained a peripheral immunoreactive myoepithelial cell layer. Conclusion.—Immunoreactivity for these 3 smooth muscle–specific proteins confirms the known neoplastic myoepithelial component of adenoid cystic carcinomas and epithelial-myoepithelial carcinomas. The consistently positive staining pattern in adenoid cystic carcinomas may be diagnostically useful in discriminating histologically similar but consistently negative polymorphous low-grade adenocarcinomas. Periductal linear staining in adenocarcinoma, not otherwise specified and salivary duct carcinomas is distinctive and appears to represent a tight cuff of myofibroblasts associated with the infiltrating glands.

scholarly journals Epidemiologic Characteristics of Salivary Gland Tumors in an Iranian Population

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Nafise Shamloo ◽  
Alireza Ghanadan ◽  
Fahimeh Sadat Hashemian ◽  
Maedeh Ghorbanpour
Keyword(s):  
Salivary Gland ◽  
Adenoid Cystic Carcinoma ◽  
Salivary Glands ◽  
Pleomorphic Adenoma ◽  
Malignant Tumors ◽  
The Body ◽  
Salivary Gland Tumors ◽  
Benign Tumors ◽  
Cross Sectional ◽  
Adenoid Cystic

Background: Salivary gland tumors include a wide variety of benign and malignant tumors in the oral and maxillofacial region. Although these tumors are not common, they are not rare. The prevalence of these tumors varies with regard to age, gender, and their location in the body. Objectives: This study aimed to evaluate the frequency of benign and malignant salivary gland tumors in patients referred to three referral hospitals in Tehran, Iran. Methods: This retrospective cross-sectional study examined the demographic and pathologic records of the patients with salivary gland tumors submitted to the Department of Pathology of Amir Alam, Loghman Hakim, and Shohada Hospitals from 2005 to 2016. In this study, the histological variants of salivary gland tumors and clinical parameters such as age, gender, and the location of the tumor were examined. The clinical data were analyzed using SPSS software version 21. Results: Of 137632 patient records, 1180 cases were salivary gland tumors. Pleomorphic adenoma in 794 cases (67.3%) and adenoid cystic carcinoma in 109 cases (9.2%) were the most common tumors, respectively. Salivary gland tumors were more common in males, and the participants’ mean age was 42.86 ± 16.5 years. The most common site was parotid and minor salivary glands, with 937 (79.4%) and 137 (12%) cases, respectively. Conclusions: In this study, the most common benign tumor was pleomorphic adenoma in the parotid gland, and the most common malignant tumor was adenoid cystic carcinoma in the major salivary glands. Furthermore, benign tumors were more frequent than malignant tumors.

Dendritic Interstitial and Myofibroblastic Cells at the Border of Salivary Gland Tumors

2001 ◽  
Vol 125 (2) ◽  
pp. 232-236
Author(s):  
Lori Soma ◽  
Virginia A. LiVolsi ◽  
Zubair W. Baloch
Keyword(s):  
Smooth Muscle ◽  
Salivary Gland ◽  
Malignant Tumors ◽  
Smooth Muscle Actin ◽  
Staining Intensity ◽  
Interstitial Cells ◽  
Salivary Gland Tumors ◽  
Benign Tumors ◽  
Low Grade ◽  
Muscle Actin

Abstract Objective.—CD34-positive dendritic interstitial cells may be associated with the regulation of tumor growth. This association has been studied in various human neoplasms, especially skin tumors. In this study, we evaluated the distribution of dendritic interstitial cells and myofibroblastic cells at the tumor periphery of various benign and malignant salivary gland neoplasms. Methods.—Forty-nine cases of salivary gland tumors were selected: 16 pleomorphic adenomas, 12 Warthin tumors, 8 polymorphous low-grade tumors, 5 adenoid cystic carcinomas, 6 acinic cell carcinomas, and 2 mucoepidermoid carcinomas. Immunohistochemical analysis was performed by using antibodies for CD34 (dendritic cells) and α-smooth muscle actin (myofibroblast) on formalin-fixed, paraffin-embedded archival tissue. Staining intensity was graded as marked (3+), moderate (2+), weak (1+), and absent (0). Results.—Staining intensity for CD34 was 3+ in 24 (86%) of 28 benign tumors (pleomorphic adenomas and Warthin tumors) and 6 (29%) of 21 malignant tumors (polymorphous low-grade tumors, acinic cell carcinomas, adenoid cystic carcinomas, and mucoepidermoid carcinomas) and 2+ in 4 (19%) of 21 malignant tumors. None of the benign tumors displayed 2+ staining with CD34. Three (11%) of 28 benign and 11 (52%) of 21 of malignant tumors failed to stain with CD34. α-Smooth muscle actin staining was 3+ in 10 (36%) of 28 benign tumors and 6 (29%) of 21 malignant tumors, and 2+ in 11 (39%) of 28 benign and 2 (9%) of 21 malignant tumors. Five (18%) of 28 benign and 11 (52%) of 21 malignant tumors failed to stain with α-smooth muscle actin. Conclusion.—We conclude that the dendritic interstitial cells and myofibroblastic cells may be associated with the regulation of tumor growth in salivary gland tumors.

The cell with a thousand faces: Detection of myoepithelial cells and their contributions in the cytological diagnosis of salivary gland tumors

2010 ◽  
Vol 40 (3) ◽  
pp. 220-227 ◽  
Author(s):  
Arzu Avcı ◽  
Ömer Günhan ◽  
Fulya Çakalaǧaoǧglu ◽  
Armagan Günal ◽  
Bülent Celasun
Keyword(s):  
Salivary Gland ◽  
Myoepithelial Cells ◽  
Salivary Gland Tumors ◽  
Cytological Diagnosis

scholarly journals Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy’s local control superior?

2014 ◽  
Vol 48 (1) ◽  
pp. 56-61 ◽  
Author(s):  
Daniel E. Spratt ◽  
Lucas Resende Salgado ◽  
Nadeem Riaz ◽  
Michael G. Doran ◽  
Moses Tam ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Local Control ◽  
Late Complications ◽  
Salivary Gland Tumors ◽  
Salivary Gland Cancer ◽  
Low Grade ◽  
Severe Toxicity ◽  
Grade 3 ◽  
Photon Radiotherapy

Abstract Background. The results of RTOG-MRC randomized trial of photon (n=15) versus neutron (n=17) therapy in the 1980’s reported an improved local control (LC) with neutron radiotherapy for unresectable salivary gland tumors. Due to increased severe toxicity with neutron radiotherapy and the paucity of neutron-therapy centers, we analyzed our institution’s results of photon radiotherapy for unresectable salivary gland tumors. Patients and methods. From 1990 to 2009, 27 patients with unresectable salivary gland cancer underwent definitive photon radiotherapy at our institution. Nodal involvement on presentation was found in 9 patients. Median dose of radiotherapy was 70 Gy. Chemotherapy was given to 18 patients, most being platinum-based regimens. Local control (LC), locoregional control (LRC), distant metastasis-free survival (DMFS), overall survival (OS), and toxicity outcomes were assessed. Results. With a median follow-up of 52.4 months, the 2/5-year actuarial LC was 69% (95%CI ± 21.0%)/55% (± 24.2%), LRC was 65% (± 21.4%)/47% (± 21.6%), and DMFS was 71% (± 21.8%)/51% (± 22.8%), respectively using competing risk analysis. The median OS was 25.7 months, and the 2/5-year OS rates were 50% (± 19.0%)/29% (± 16.6%), respectively. Higher histologic grade was significant for an increased rate of DM (intermediate grade vs. low grade, p=0.04, HR 7.93; high grade vs. low grade, p=0.01, HR 13.50). Thirteen (48%) patient’s experienced acute grade 3 toxicity. Late grade 3 toxicity occurred in three (11%) patients. Conclusions. Our data compares favorably to neutron radiotherapy with fewer late complications. Photon radiotherapy is an acceptable alternative to neutron radiotherapy in patients who present with unresectable salivary gland tumors.

Sign in / Sign up

Export Citation Format

Share Document